LianBio (LIAN)
0.32
0.00 (0.31%)
At close: Jan 16, 2025, 9:00 PM
0.31% (1D)
| Bid | n/a |
| Market Cap | 34.47M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -87.98M |
| EPS (ttm) | -0.82 |
| PE Ratio (ttm) | -0.38902439024390245 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 2,485,055 |
| Avg. Volume (20D) | 959,835 |
| Open | 0.31 |
| Previous Close | 0.32 |
| Day's Range | 0.31 - 0.32 |
| 52-Week Range | 0.24 - 4.99 |
| Beta | 0.23 |
About LIAN
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 1, 2021
Employees 163
Stock Exchange NASDAQ
Ticker Symbol LIAN
Website https://www.lianbio.com